Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells 8,787 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel sold 8,787 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00. Following the completion of the sale, the director directly owned 27,277 shares in the company, valued at approximately $1,445,681. The trade was a 24.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Georges Gemayel also recently made the following trade(s):

• On Thursday, March 5th, Georges Gemayel sold 10,000 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $53.71, for a total value of $537,100.00.

Supernus Pharmaceuticals Stock Up 0.6%

Shares of SUPN traded up $0.30 during mid-day trading on Monday, reaching $54.17. The company had a trading volume of 799,891 shares, compared to its average volume of 785,366. The stock has a market capitalization of $3.12 billion, a P/E ratio of -79.66, a PEG ratio of 1.67 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $59.68. The stock has a 50 day moving average of $50.99 and a two-hundred day moving average of $48.82.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SUPN shares. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Supernus Pharmaceuticals has an average rating of “Hold” and an average target price of $62.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SUPN. Hantz Financial Services Inc. grew its stake in Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares during the period. Torren Management LLC acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth $49,000. USA Financial Formulas purchased a new position in Supernus Pharmaceuticals during the third quarter valued at $50,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $51,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.